Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v17-EN | Version v8-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2023-09-27 | 2023-06-14 |
| Drug Identification Number | 00533688 | 00533688 |
| Brand name | TOBRAMYCIN FOR INJECTION | TOBRAMYCIN FOR INJECTION |
| Common or Proper name | TOBRAMYCIN FOR INJECTION | TOBRAMYCIN FOR INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | TOBRAMYCIN | TOBRAMYCIN |
| Strength(s) | 1.2G | 1.2G |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 50 mL | 50 mL |
| ATC code | J01GB | J01GB |
| ATC description | AMINOGLYCOSIDE ANTIBACTERIALS | AMINOGLYCOSIDE ANTIBACTERIALS |
| Reason for shortage | Delay in shipping of the drug. | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2022-09-20 | 2022-09-20 |
| Estimated end date | 2023-09-27 | 2023-08-15 |
| Actual end date | 2023-09-26 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be extending the backorder on our Tobramycin for Injection, 1.2 g PBP Vial 50 mL until September 27, 2023. | On 50% allocation in June 2023. Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Tobramycin for Injection 1.2 g PBP Vial 50 mL effective July 1, 2023, until August 15, 2023. During this time, allocations for our Tobramycin Injection 40 mg/mL MD Vial 30 mL will be increased to provide coverage. Contract customers will be allocated 100% of historical 30 mL demand plus 100% of historical 50 mL demand at a 1:1 ratio (1 vial of 30 mL = 1 vial of 50 mL). |
| Health Canada comments |